John Libbey Eurotext

European Journal of Dermatology

Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria Volume 27, numéro 5, September-October 2017

Figure 1

Time to achieve first well-controlled (UAS7≤6) or complete (UAS7 = 0) response in ASTERIA I and GLACIAL. Reproduced from Kaplan et al. [33]. CC BY-NC-ND 4.0. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Figure 2

Recommended treatment for complete, partial or non-responders to omalizumab: (a) during the first 1-3 months of treatment, it is important to define the response profile of the patient; (b) if no response during the first 1-3 months, consider reassessing the diagnosis e.g. autoinflammation/autoimmunity; (c) if there is a partial response during the first 1-3 months, consider optimizing dose/dosing intervals/both; (d) in patients with an early “flare-up” before the end of the four-week dosing period, consider shortening the dosing intervals; (e) if partial response for 3-6 months, consider reassessing the diagnosis (if no reassessment occurred at 1-3 months); (f) if complete response has been present for 3-6 months, consider tapering or discontinuing to assess for spontaneous remission.*The presence or absence of angioedema should also be considered using AAS. ‡ Also dependent on physician judgement and patient expectations based on previous disease activity.